A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
  • Consensus Rating: Buy
  • Consensus Price Target: $229.75
  • Forecasted Upside: 31.88 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$174.21
▲ +2.32 (1.35%)

This chart shows the closing price for ZTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zoetis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZTS

Analyst Price Target is $229.75
▲ +31.88% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $229.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 31.88% upside from the last price of $174.21.

This chart shows the closing price for ZTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Zoetis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/24/2022Stifel NicolausLower Price TargetBuy$275.00 ➝ $225.00Low
5/19/2022The Goldman Sachs GroupLower Price TargetBuy$237.00 ➝ $208.00Low
3/9/2022CitigroupLower Price TargetNeutral$232.00 ➝ $208.00High
12/20/2021CitigroupBoost Price TargetNeutral$184.00 ➝ $232.00Medium
11/18/2021Morgan StanleyInitiated CoverageOverweight$264.00High
11/5/2021BarclaysBoost Price TargetOverweight$235.00 ➝ $240.00High
8/25/2021ArgusBoost Price TargetBuy$195.00 ➝ $225.00Low
8/9/2021Credit Suisse GroupBoost Price TargetOutperform$206.00 ➝ $230.00Low
8/6/2021BarclaysBoost Price TargetOverweight$208.00 ➝ $235.00Low
7/16/2021Raymond JamesDowngradeOutperform ➝ Market PerformLow
7/13/2021Cantor FitzgeraldBoost Price TargetOverweight$210.00 ➝ $238.00Low
5/28/2021ArgusBoost Price TargetBuy$185.00 ➝ $195.00Medium
5/12/2021CitigroupBoost Price Target$175.00 ➝ $184.00Medium
5/7/2021Raymond JamesBoost Price TargetOutperform$166.00 ➝ $192.00Medium
5/7/2021BarclaysBoost Price TargetOverweight$200.00 ➝ $208.00Medium
3/8/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$166.00Medium
3/8/2021Bank of AmericaUpgradeNeutral ➝ Buy$180.00Medium
2/17/2021Credit Suisse GroupBoost Price Target$197.00 ➝ $203.00Low
11/13/2020Morgan StanleyBoost Price TargetEqual Weight$167.00 ➝ $174.00Low
11/12/2020Truist FinancialBoost Price Target$160.00 ➝ $170.00Low
11/6/2020BarclaysBoost Price TargetOverweight$175.00 ➝ $189.00Medium
9/21/2020Atlantic SecuritiesInitiated CoverageOverweight$191.00Low
8/20/2020Morgan StanleyBoost Price TargetNeutral ➝ Equal Weight$125.00 ➝ $167.00Low
8/14/2020Edward JonesUpgradeHold ➝ BuyLow
8/12/2020G.ResearchDowngradeBuy ➝ HoldLow
8/12/2020GabelliDowngradeBuy ➝ HoldLow
8/10/2020Truist FinancialBoost Price TargetNeutral ➝ Hold$112.00 ➝ $160.00Low
8/10/2020CitigroupBoost Price TargetNeutral$146.00 ➝ $160.00Low
8/7/2020Stifel NicolausBoost Price TargetTop Pick ➝ Buy$155.00 ➝ $170.00Medium
7/30/2020CitigroupBoost Price TargetNeutral$131.00 ➝ $146.00Medium
7/20/2020Bank of AmericaBoost Price TargetNeutral$135.00 ➝ $150.00Medium
6/3/2020ArgusReiterated RatingBuyLow
5/27/2020Jefferies Financial GroupInitiated CoverageBuy$152.00High
5/18/2020Credit Suisse GroupReiterated RatingBuy$147.00High
5/8/2020UBS GroupLower Price TargetNeutral$146.00 ➝ $126.00Low
5/8/2020CitigroupLower Price TargetNeutral$139.00 ➝ $131.00Low
5/7/2020BarclaysBoost Price TargetOverweight$129.00 ➝ $140.00Medium
4/2/2020Morgan StanleyLower Price TargetEqual Weight$148.00 ➝ $125.00High
3/31/2020G.ResearchUpgradeHold ➝ BuyHigh
2/28/2020The Goldman Sachs GroupReiterated RatingBuy$162.00High
2/19/2020UBS GroupBoost Price TargetNeutral$126.00 ➝ $146.00Low
2/14/2020Morgan StanleyBoost Price TargetEqual Weight$136.00 ➝ $148.00Low
2/14/2020SunTrust BanksReiterated RatingHold$145.00Low
2/13/2020CfraUpgradeBuy ➝ Strong-Buy$147.00 ➝ $160.00Low
2/12/2020Bank of AmericaReiterated RatingHold$145.00Medium
1/9/2020Raymond JamesInitiated CoverageMarket PerformLow
12/5/2019Bank of AmericaReiterated RatingHold$125.00Low
10/11/2019Credit Suisse GroupSet Price TargetBuy$138.00Low
9/30/2019Morgan StanleyBoost Price TargetHold ➝ Equal Weight$100.00 ➝ $136.00Low
9/13/2019Stifel NicolausSet Price TargetBuy$140.00Medium
9/11/2019Credit Suisse GroupReiterated RatingBuy$130.00High
9/9/2019The Goldman Sachs GroupInitiated CoverageConviction-Buy$145.00Medium
9/4/2019ArgusSet Price TargetBuy$140.00Low
8/13/2019SunTrust BanksBoost Price TargetHold$120.00 ➝ $130.00Low
8/7/2019Craig HallumBoost Price TargetBuy$132.00 ➝ $138.00Low
8/7/2019BarclaysBoost Price TargetOverweight$120.00 ➝ $135.00Low
7/22/2019Stifel NicolausBoost Price TargetBuy$110.00 ➝ $130.00Medium
7/1/2019Bank of AmericaDowngradeBuy ➝ Neutral$111.00 ➝ $120.00Low
6/25/2019Craig HallumBoost Price TargetBuy$114.00 ➝ $132.00Low
6/12/2019Cantor FitzgeraldReiterated RatingOverweight$116.00 ➝ $130.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$120.00Low
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$114.00Low
5/9/2019BMO Capital MarketsBoost Price TargetMarket Perform$101.00 ➝ $105.00Low
5/2/2019GabelliDowngradeBuy ➝ Hold$108.00Low
4/2/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $112.00Low
3/20/2019UBS GroupInitiated CoverageNeutralLow
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$100.00Low
3/4/2019Stifel NicolausUpgradeHold ➝ Buy$97.00 ➝ $110.00Medium
2/25/2019BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$93.00 ➝ $101.00Low
1/23/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$86.00Low
11/13/2018ArgusSet Price TargetBuy$105.00Medium
11/12/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Neutral$93.00Low
11/11/2018BMO Capital MarketsReiterated RatingHoldLow
11/2/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$100.00 ➝ $101.00Low
11/2/2018Morgan StanleySet Price TargetHold$100.00Low
10/17/2018Cantor FitzgeraldReiterated RatingOverweight$98.00 ➝ $105.00Low
10/15/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00Medium
10/1/2018Cantor FitzgeraldReiterated RatingBuy$98.00Low
8/21/2018Stifel NicolausDowngradeBuy ➝ Hold$95.00High
8/14/2018ArgusBoost Price TargetBuy ➝ Buy$90.00 ➝ $103.00Low
8/3/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$86.00 ➝ $95.00Low
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Hold$87.00 ➝ $92.00Low
8/2/2018BMO Capital MarketsReiterated RatingHold$82.00High
8/2/2018Cantor FitzgeraldSet Price TargetBuy$98.00High
7/30/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$97.00 ➝ $100.00Low
7/27/2018Cantor FitzgeraldSet Price TargetBuy$98.00Low
7/13/2018Jefferies Financial GroupSet Price TargetBuy$96.00Medium
6/6/2018Cantor FitzgeraldSet Price TargetBuy$98.00Low
5/16/2018BMO Capital MarketsReiterated RatingHold$80.00Low
5/16/2018Cantor FitzgeraldReiterated RatingBuy$98.00Low
5/1/2018Cantor FitzgeraldSet Price TargetBuy$90.00Low
4/25/2018Craig HallumReiterated RatingBuy$87.00 ➝ $94.00Low
4/24/2018Cantor FitzgeraldSet Price TargetBuy$90.00Medium
4/19/2018Hilliard LyonsDowngradeNeutralLow
4/19/2018CitigroupReiterated RatingBuy ➝ Buy$85.00 ➝ $98.00Low
4/13/2018Jefferies Financial GroupReiterated RatingBuy$96.00Low
4/5/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$83.00 ➝ $89.00Low
3/19/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$70.00Low
2/26/2018Jefferies Financial GroupSet Price TargetBuy$97.00Low
2/17/2018BarclaysSet Price TargetHold$77.00Medium
2/16/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$76.00 ➝ $78.00Low
2/16/2018Piper Jaffray CompaniesSet Price TargetBuy$88.00Low
2/16/2018Stifel NicolausReiterated RatingBuy ➝ Buy$84.00 ➝ $86.00Medium
2/16/2018Bank of AmericaBoost Price TargetBuy$80.00 ➝ $87.00Medium
2/15/2018Cantor FitzgeraldSet Price TargetBuy$90.00Medium
2/15/2018BMO Capital MarketsSet Price TargetHold$78.00Medium
2/15/2018CowenSet Price TargetBuy$85.00Medium
1/22/2018BMO Capital MarketsSet Price TargetHold$78.00Low
1/18/2018Piper Jaffray CompaniesReiterated RatingBuy$86.00Low
1/16/2018Jefferies Financial GroupReiterated RatingBuy$89.00High
1/11/2018Cantor FitzgeraldSet Price TargetBuy$85.00Low
1/9/2018BMO Capital MarketsBoost Price TargetPositive ➝ Market Perform$78.00Medium
1/8/2018BMO Capital MarketsReiterated RatingHoldLow
1/4/2018CitigroupUpgradeNeutral ➝ Buy$85.00Low
1/2/2018Craig HallumReiterated RatingBuy$77.00 ➝ $85.00Low
1/2/2018Cantor FitzgeraldSet Price TargetBuy$85.00Low
12/26/2017Cantor FitzgeraldSet Price TargetBuy$85.00Low
12/12/2017Cantor FitzgeraldSet Price TargetBuy$80.00Low
11/29/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$80.00Low
11/24/2017UBS GroupReiterated RatingBuy ➝ NeutralN/A
11/17/2017CowenSet Price TargetBuy$70.00 ➝ $80.00N/A
11/10/2017Jefferies Financial GroupReiterated RatingBuyN/A
11/3/2017BMO Capital MarketsBoost Price TargetMarket Perform$65.00 ➝ $70.00N/A
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$61.00 ➝ $70.00N/A
11/2/2017BMO Capital MarketsReiterated RatingHold$65.00N/A
10/31/2017Cantor FitzgeraldSet Price TargetBuy$75.00N/A
10/25/2017BMO Capital MarketsSet Price TargetHold$65.00N/A
10/24/2017Cantor FitzgeraldReiterated RatingBuy$75.00N/A
10/24/2017Stifel NicolausReiterated RatingBuy$65.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$75.00Low
9/6/2017Cantor FitzgeraldReiterated RatingBuy$75.00Low
9/1/2017Stifel NicolausReiterated RatingBuy$65.00Low
8/25/2017Piper Jaffray CompaniesSet Price TargetBuy$73.00Low
8/24/2017CowenSet Price TargetBuy$70.00Low
8/14/2017Cantor FitzgeraldSet Price TargetBuy$75.00Low
8/7/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$62.00Low
7/25/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$65.00High
7/21/2017Stifel NicolausReiterated RatingBuy$65.00Low
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$62.00 ➝ $65.00Low
7/17/2017CowenSet Price TargetBuy$70.00Low
7/11/2017CowenSet Price TargetBuy$60.00Low
(Data available from 7/4/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/6/2021
  • 2 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/5/2022
  • 4 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/4/2022
  • 6 very positive mentions
  • 32 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/5/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/5/2022
  • 4 very positive mentions
  • 40 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
6/4/2022
  • 10 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 10 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Zoetis logo
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $174.21
Low: $170.50
High: $174.50

50 Day Range

MA: $167.68
Low: $155.97
High: $181.31

52 Week Range

Now: $174.21
Low: $154.18
High: $249.27

Volume

71,713 shs

Average Volume

2,378,639 shs

Market Capitalization

$81.99 billion

P/E Ratio

39.96

Dividend Yield

0.75%

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

The following Wall Street analysts have issued research reports on Zoetis in the last twelve months: Argus, Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Morgan Stanley, Raymond James, Stifel Nicolaus, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ZTS.

What is the current price target for Zoetis?

0 Wall Street analysts have set twelve-month price targets for Zoetis in the last year. Their average twelve-month price target is $229.75, suggesting a possible upside of 31.9%.
View the latest price targets for ZTS.

What is the current consensus analyst rating for Zoetis?

Zoetis currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZTS will outperform the market and that investors should add to their positions of Zoetis.
View the latest ratings for ZTS.

How do I contact Zoetis' investor relations team?

Zoetis' physical mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company's listed phone number is (973) 822-7000 and its investor relations email address is [email protected] The official website for Zoetis is www.zoetis.com. Learn More about contacing Zoetis investor relations.

A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!